← All trials
NCT07163143
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Nov 30, 2028
- Completion date
- Apr 30, 2029
- First posted
- Sep 9, 2025
- Last posted
- Sep 9, 2025
- Enrollment
- 784
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- Wits Health Consortium (Pty) LtdCollaborator
- KTH Royal Institute of TechnologyCollaborator
- Foundation for Innovative New Diagnostics, SwitzerlandCollaborator
- University of LondonCollaborator
- Aurum InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.